Vectibix is a medicine for treating colorectal (bowel) cancer that has spread to other parts of the body. Vectibix is used alone or with other cancer medicines in patients with a type of tumour that has normal
(‘wild-type’) copies of a gene known as RAS.
It contains the active substance panitumumab.
Vectibix : EPAR - Medicine overview (PDF/118.7 KB)
First published: 18/06/2009
Last updated: 24/01/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Amgen Europe B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
05/07/2022 Vectibix - EMEA/H/C/000741 - IA/0100
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC):
- in first-line in combination with Folfox or Folfiri.
- in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).
- as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 201527/02/2015